ARID1B loss drives sorafenib resistance through transcriptional reprogramming in hepatocellular carcinoma
Ontology highlight
ABSTRACT: mRNA-seq was performed in HepG2 hepatocellular carcinoma cells to characterize transcriptional changes driven by ARID1B loss under sorafenib treatment. Wild-type (WT) and ARID1B-knockout (ARID1B-KO) HepG2 cells were treated with sorafenib (5 µM, 48 h) or DMSO vehicle, with three biological replicates per condition. DESeq2 interaction model identified ARID1B-dependent transcriptional responses to sorafenib. Preprint: https://doi.org/10.64898/2026.06.11.731725
ORGANISM(S): Homo sapiens
PROVIDER: GSE335769 | GEO | 2026/06/19
REPOSITORIES: GEO
ACCESS DATA